Tariquidar
Appearance
This article relies largely or entirely on a single source. (August 2014) |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C38H38N4O6 |
Molar mass | 646.744 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Tariquidar (INN/USAN) is a P-glycoprotein inhibitor[1] undergoing research as an adjuvant against multidrug resistance in cancer.
References
[edit]- ^ Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE (March 2008). "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R))". Biochemical Pharmacology. 75 (6): 1302–12. doi:10.1016/j.bcp.2007.12.001. PMC 2346578. PMID 18234154.1302-12&rft.date=2008-03&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2346578#id-name=PMC&rft_id=info:pmid/18234154&rft_id=info:doi/10.1016/j.bcp.2007.12.001&rft.aulast=Robey&rft.aufirst=RW&rft.au=Shukla, S&rft.au=Finley, EM&rft.au=Oldham, RK&rft.au=Barnett, D&rft.au=Ambudkar, SV&rft.au=Fojo, T&rft.au=Bates, SE&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2346578&rfr_id=info:sid/en.wikipedia.org:Tariquidar" class="Z3988">